{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"HUMA","limit":50},"count":50,"signals":[{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":28,"context":"lar conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. In April 2023, we announced completion of enrollment of our V007 Phase 3 trial of the ATEV for use in AV access for hemodialysis. In July 2024, we announced positive topline results from our V007 Phase 3 trial, where the ATEV met the co-primary endp","filed_date":"2026-03-27","accession":"0001818382-26-000004","full_text":"https://origin.rootz.global/static/filing/0001818382-26-000004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":80,"context":"ers, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. Any FDA enforcement action could have a material adverse effect on us. Marketing Approval Biological Products in the United States Before a biologic is approved in the United States, an applicant must submit a BLA that includes sufficient evidence to establish th","filed_date":"2026-03-27","accession":"0001818382-26-000004","full_text":"https://origin.rootz.global/static/filing/0001818382-26-000004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":27,"context":"ata shall have the meaning ascribed to such term in Section 3.1(ii). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Per Share Purchase Price equals $0.80 subject to adjus","filed_date":"2026-03-19","accession":"0001104659-26-032116","full_text":"https://origin.rootz.global/static/filing/0001104659-26-032116.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":37,"context":"ault or Event of Default shall have occurred and be continuing or result from the proposed Loan; (d)there has not been any event or circumstance that has had or could reasonably be expected to have a Material Adverse Effect; (e) each Loan Party shall have executed and delivered such amendments or supplements to this Agreement and any other Loan Documents, financing statements and third-party waivers as Administrative Ag","filed_date":"2025-12-15","accession":"0001104659-25-121214","full_text":"https://origin.rootz.global/static/filing/0001104659-25-121214.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":67,"context":"ction 3.01 Organization. 37 Section 3.02 Authorization. 37 Section 3.03 Enforceability. 38 Section 3.04 Governmental Authorization. 38 Section 3.05 Ownership. 38 Section 3.06 Financial Statements; No Material Adverse Effect. 38 Section 3.07 No Undisclosed Liabilities. 39 Section 3.08 Solvency; No Fraudulent Transfer. 39 Section 3.09 Litigation. 39 Section 3.10 Compliance with Laws. 40 Section 3.11 Conflicts; Adverse Agr","filed_date":"2025-09-18","accession":"0001104659-25-090963","full_text":"https://origin.rootz.global/static/filing/0001104659-25-090963.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":22,"context":"novation, Dr. Bamforth spent 30 years at Eli Lilly and Company (Lilly) until his retirement in 2018, in an array of roles primarily focused on brand development and commercialization. In 2012, he was appointed Chief Marketing Officer for Lillys multi-billion-dollar U.S. business and in 2016 he became Chief Marketing Officer for Lillys global business. Dr. Bamforth currently sits on the board of directors of READDI (Rapidly Emergi","filed_date":"2025-04-29","accession":"0001818382-25-000066","full_text":"https://origin.rootz.global/static/filing/0001818382-25-000066.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":30,"context":"lar conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. In April 2023, we announced completion of enrollment of our V007 Phase 3 trial of the ATEV for use in AV access for hemodialysis. In July 2024, we announced positive topline results from our V007 Phase 3 trial, where the ATEV met the co-primary endp","filed_date":"2025-03-31","accession":"0001818382-25-000034","full_text":"https://origin.rootz.global/static/filing/0001818382-25-000034.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":81,"context":"ers, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. Any FDA enforcement action could have a material adverse effect on us. Marketing Approval Biological Products in the United States Before a biologic is approved in the United States, an applicant must submit a BLA that includes sufficient evidence to establish th","filed_date":"2025-03-31","accession":"0001818382-25-000034","full_text":"https://origin.rootz.global/static/filing/0001818382-25-000034.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":18,"context":"Company with the SEC pursuant to Rule 424(b)(5) under the Securities Act and in accordance with Section 5(a) hereof, together with all documents and information incorporated therein by reference. (cc)Material Adverse Effect means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the results of operations, assets, business or financial condition of the Company and its Subsidiaries, t","filed_date":"2024-09-25","accession":"0001104659-24-102498","full_text":"https://origin.rootz.global/static/filing/0001104659-24-102498.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":22,"context":"novation, Dr. Bamforth spent 30 years at Eli Lilly and Company (Lilly) until his retirement in 2018, in an array of roles primarily focused on brand development and commercialization. In 2012, he was appointed Chief Marketing Officer for Lillys multi-billion-dollar U.S. business and in 2016 he became Chief Marketing Officer for Lillys global business. Dr. Bamforth currently sits on the board of directors of READDI (Rapidly Emergi","filed_date":"2024-04-29","accession":"0001818382-24-000047","full_text":"https://origin.rootz.global/static/filing/0001818382-24-000047.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":26,"context":"rity Review and set a Prescription Drug User Fee Act (PDUFA) date, the FDA action date for its regulatory decision regarding the BLA, of August 10, 2024. In April 2023, we announced completion of enrollment of our V007 Phase 3 trial of the HAV for use in AV access for hemodialysis. Upon anticipated completion of our V007 Phase 3 trial in 2024, and dependent upon clinical results, we intend to submit","filed_date":"2024-03-28","accession":"0001818382-24-000040","full_text":"https://origin.rootz.global/static/filing/0001818382-24-000040.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":82,"context":"ers, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. Any FDA enforcement action could have a material adverse effect on us. Marketing Approval Biological Products in the United States Before a biologic is approved in the United States, an applicant must submit a BLA that includes sufficient evidence to establish th","filed_date":"2024-03-28","accession":"0001818382-24-000040","full_text":"https://origin.rootz.global/static/filing/0001818382-24-000040.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":22,"context":"i03fb363fefe64bef8356526b0a482b7f_7) PROPOSAL2 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Upon the recommendation of the Audit Committee of the Board, the Board has selected Pricewaterhouse Coopers LLP (PwC) as our independent registered public accounting firm to perform the audit of our financial statements for the year ending December 31, 2023, and has further directed that management sub","filed_date":"2023-04-28","accession":"0001818382-23-000021","full_text":"https://origin.rootz.global/static/filing/0001818382-23-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"cal and Pre-Clinical Stage Product Pipeline The following table highlights key information about our current product pipeline: We began clinical evaluations of our HAVs in December 2012, with the enrollment of the first Phase 2 patient in our V001 hemodialysis access trial in Europe. Since then, we have completed one Phase 2 trial in the United States, and currently have seven trials either actively","filed_date":"2023-03-24","accession":"0001818382-23-000016","full_text":"https://origin.rootz.global/static/filing/0001818382-23-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":33,"context":"ers, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. Any FDA enforcement action could have a material adverse effect on us. Marketing Approval Biological Products in the United States Before a biologic is approved in the United States, an applicant must submit a BLA that includes sufficient evidence to establish th","filed_date":"2023-03-24","accession":"0001818382-23-000016","full_text":"https://origin.rootz.global/static/filing/0001818382-23-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"made to Humacytes named executive officers in 2021 are outlined below in Outstanding Equity Awards as of December 31, 2021. The option award granted to Dr. Niklason in 2021 vests in equal annual installments on each of the first three anniversaries of November 9, 2020, subject to acceleration upon a corporate transaction (as defined in Humacytes 2015 Omnibus Incentive Plan, as amended (the 2015 Plan)","filed_date":"2022-04-29","accession":"0001818382-22-000028","full_text":"https://origin.rootz.global/static/filing/0001818382-22-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":23,"context":"ic383b04632124ed9afd6f4f7a73df087_7) PROPOSAL2 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Upon the recommendation of the Audit Committee of the Board, the Board has selected Pricewaterhouse Coopers LLP (PwC) as our independent registered public accounting firm to perform the audit of our financial statements for the year ending December31, 2022, and has further directed that management subm","filed_date":"2022-04-29","accession":"0001818382-22-000028","full_text":"https://origin.rootz.global/static/filing/0001818382-22-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":33,"context":"the HAV product. In this study, we observed that HAVs produced in the LUNA200 system were comparable to HAVs used in our Phase III trials. Additionally, a crossover study, called V011, completed enrollment of 30 subjects to evaluate HAVs that are manufactured on Humacytes commercial LUNA200 platform with the primary goal to evaluate the safety, efficacy and immunogenicity of the LUNA200-manufactured","filed_date":"2022-03-29","accession":"0001818382-22-000011","full_text":"https://origin.rootz.global/static/filing/0001818382-22-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":34,"context":"ers, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. Any FDA enforcement action could have a material adverse effect on us. Marketing Approval Biological Products in the United States Before a biologic is approved in the United States, an applicant must submit a BLA that includes sufficient evidence to establish th","filed_date":"2022-03-29","accession":"0001818382-22-000011","full_text":"https://origin.rootz.global/static/filing/0001818382-22-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":24,"context":"hased shares of series D redeemable convertible preferred stock that at the Closing of the Merger converted into 15,812,735 shares of the Companys common stock. In August 2021, Fresenius Medical Care invested $25 million as part of the PIPE Financing and received 2.5 million shares of the Companys common stock. In addition, the Company entered into a distribution agreement with Fresenius Medical Care in June 2018 whi","filed_date":"2022-03-29","accession":"0001818382-22-000011","full_text":"https://origin.rootz.global/static/filing/0001818382-22-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":37,"context":"experience significant delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.  We may experience delays or difficulties in the enrollment of patients in our clinical trials, which may delay or prevent additional clinical trials and our receipt of necessary marketing approvals.  Lack of experience by investigators and surgeons with o","filed_date":"2021-10-22","accession":"0001104659-21-128615","full_text":"https://origin.rootz.global/static/filing/0001104659-21-128615.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":34,"context":"ights for our proprietary scientific technology platform and product candidates.  We may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and stock price, which could cause you to lose some or all of your investment.  Risks Related to the Development and Commercialization of Our Product","filed_date":"2021-10-22","accession":"0001104659-21-128615","full_text":"https://origin.rootz.global/static/filing/0001104659-21-128615.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":29,"context":"referred stock effective immediately prior to the closing.  (5) Reflects the payment of direct and incremental transaction costs incurred prior to or concurrent with the Business Combination and PIPE Investment of $20.0million, which were cash settled upon closing in accordance with the Business Combination Agreement. Transaction costs includes legal, accounting, financial advisory and other professional fees related to th","filed_date":"2021-10-22","accession":"0001104659-21-128615","full_text":"https://origin.rootz.global/static/filing/0001104659-21-128615.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":37,"context":"e significant delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. | | | | | We may experience delays or difficulties in the enrollment of patients in our clinical trials, which may delay or prevent additional clinical trials and our receipt of necessary marketing approvals. | | | | | Lack of experience by investigators and surgeo","filed_date":"2021-09-17","accession":"0001104659-21-116962","full_text":"https://origin.rootz.global/static/filing/0001104659-21-116962.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":34,"context":"our proprietary scientific technology platform and product candidates. | | | | | We may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and stock price, which could cause you to lose some or all of your investment. | | Risks Related to the Development and Commercialization of Our Prod","filed_date":"2021-09-17","accession":"0001104659-21-116962","full_text":"https://origin.rootz.global/static/filing/0001104659-21-116962.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":29,"context":"stock effective immediately prior to the closing. | | | | (5) | Reflects the payment of direct and incremental transaction costs incurred prior to or concurrent with the Business Combination and PIPE Investment of $20.0 million, which were cash settled upon closing in accordance with the Business Combination Agreement. Transaction costs includes legal, accounting, financial advisory and other professional fees related to th","filed_date":"2021-09-17","accession":"0001104659-21-116962","full_text":"https://origin.rootz.global/static/filing/0001104659-21-116962.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":9,"context":"nitial business combination with only a single entity, our lack of diversification may: |  | | subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination, and |  | |  | | cause us to depend on the marketing and sale of a single product or limited number of products o","filed_date":"2021-05-14","accession":"0001213900-21-026404","full_text":"https://origin.rootz.global/static/filing/0001213900-21-026404.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":9,"context":"nitial business combination with only a single entity, our lack of diversification may: |  | | subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination, and |  | |  | | cause us to depend on the marketing and sale of a single product or limited number of products o","filed_date":"2021-02-16","accession":"0001213900-21-009571","full_text":"https://origin.rootz.global/static/filing/0001213900-21-009571.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"rity, which by its terms bears interest only after Maturity, means interest payable after Maturity. Interest Payment Date, when used with respect to any Security, means the Stated Maturity of an installment of interest on such Security. Investment Company Act means the Investment Company Act of 1940 and any statute successor thereto, in each case as amended from time to time. Maturity, when used with","filed_date":"2025-09-12","accession":"0001104659-25-089607","full_text":"https://origin.rootz.global/static/filing/0001104659-25-089607.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"- CREATING MILESTONES File BLA in Trauma 2022 Submit for Marketing Approval in Trauma 2023 PAD V004 2 - year Readout 2022 Initiate Phase 3 PAD trial 2022 V011 1 - year AV Results 2021 V007 Finish Enrollment 2021 V007 1 - year AV Results 2023 F il e A V Acc e ss B L A 20 2 3 Submit for Marketing Approval in A V Acc e ss 2 0 2 3 All milestone dates are only management estimates based on currently avail","filed_date":"2021-06-07","accession":"0001213900-21-031280","full_text":"https://origin.rootz.global/static/filing/0001213900-21-031280.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"DA accepted the Companys Biologics License Application (BLA) for an indication in vascular trauma, and in accordance with the Purchase Agreement, on March 11, 2024, the Company drew a subsequent installment of $20.0million.In accordance with the amended Purchase Agreement, the Company was entitled to draw up to $90.0million in subsequent installments subject to the terms and conditions set forth in t","filed_date":"2025-08-11","accession":"0001818382-25-000125","full_text":"https://origin.rootz.global/static/filing/0001818382-25-000125.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"DA accepted the Companys Biologics License Application (BLA) for an indication in vascular trauma, and in accordance with the Purchase Agreement, on March 11, 2024, the Company drew a subsequent installment of $20.0million.In accordance with the amended Purchase Agreement, the Company was entitled to draw up to $90.0million in subsequent installments subject to the terms and conditions set forth in t","filed_date":"2025-05-13","accession":"0001818382-25-000076","full_text":"https://origin.rootz.global/static/filing/0001818382-25-000076.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"DA accepted the Companys Biologics License Application (BLA) for an indication in vascular trauma, and in accordance with the Purchase Agreement, on March 11, 2024, the Company drew a subsequent installment of $20.0million.The FDA granted full approval for the Companys BLA on December 19, 2024, and the Company elected not to draw the additional $40.0million that became available under the Purchase Ag","filed_date":"2025-11-12","accession":"0001818382-25-000132","full_text":"https://origin.rootz.global/static/filing/0001818382-25-000132.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"ebt. In February 2024, the FDA accepted the Companys BLA for an indication in vascular trauma, and in accordance with the Purchase Agreement, on March 11, 2024, the Company received a subsequent installment of $20.0million.As of September30, 2024, the Company is entitled to receive up to approximately $90.0million in subsequent installments subject to the terms and conditions set forth in the Purchas","filed_date":"2024-11-08","accession":"0001818382-24-000199","full_text":"https://origin.rootz.global/static/filing/0001818382-24-000199.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"uded in other income (expense), net | 109 | | | Fair value as of end of period | $ | (4,079) | | ___________________________(1)Represents an increase in debt discount upon issuance of the second installment under the Purchase Agreement. See Note 6 for further information.4. Property and Equipment, NetProperty and equipment, net consist of the following: | | | ($ in thousands) | March 31,2024 | Decemb","filed_date":"2024-05-13","accession":"0001818382-24-000056","full_text":"https://origin.rootz.global/static/filing/0001818382-24-000056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":72,"match_count":9,"context":", less certain transaction expenses, which was used to repay in full the Companys then-existing obligations under the former loan agreement with SVB. In March 2024, the Company drew a subsequent installment of $20.0 million, and elected not to draw the additional $40.0 million that later became available under the Purchase Agreement. On September 17, 2025, the Company and Humacyte Global, Inc. entere","filed_date":"2026-08-12","accession":"0001193125-26-347022","full_text":"https://origin.rootz.global/static/filing/0001193125-26-347022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"ebt. In February 2024, the FDA accepted the Companys BLA for an indication in vascular trauma, and in accordance with the Purchase Agreement, on March 11, 2024, the Company received a subsequent installment of $20.0million.17 Table of ContentsHumacyte, Inc.Notes to Condensed Consolidated Financial Statements(unaudited)As of June30, 2024, the Company is entitled to receive up to approximately $90.0mil","filed_date":"2024-08-13","accession":"0001818382-24-000156","full_text":"https://origin.rootz.global/static/filing/0001818382-24-000156.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"| | | | | | Advance approval of the HAV for use in arteriovenous (AV) access for hemodialysis by, among other items, (i) reaching agreement with the FDA on a BLA filing strategy, (ii) completing enrollment of the V007 Phase 3 clinical trial and (iii) reaching agreement with the FDA on the clinical trial protocol for our V012 Phase 3 clinical trial and commencing enrollment. | | | | | | | | Advance p","filed_date":"2024-04-29","accession":"0001818382-24-000047","full_text":"https://origin.rootz.global/static/filing/0001818382-24-000047.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"ny-branding/aHVtYWN5dGUuY29t/images/2025-04-04_logo.svg --- EX-99.1 2 huma-20230814xexx991.htm EX-99.1 Exhibit 99.1 Humacyte Second Quarter 2023 Financial Results and Business Update Completed Enrollment in Phase 23 V005 Trial of HAV in Vascular Trauma Repair Top-Line Results on Track for Q3 2023  Results from Vascular Trauma Humanitarian Program in Ukraine Highlighted at 2023 Military Health Syst","filed_date":"2023-08-14","accession":"0001818382-23-000112","full_text":"https://origin.rootz.global/static/filing/0001818382-23-000112.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"commencement date, after which 148th of the option will become exercisable on the 4th of each month through April 4, 2026. The option award granted to Dr. Niklason in 2021 vests in equal annual installments on each of the first three anniversaries of November 9, 2020, subject to acceleration upon a corporate transaction (as defined in Humacytes 2015 Omnibus Incentive Plan, as amended (the 2015 Plan)","filed_date":"2023-04-28","accession":"0001818382-23-000021","full_text":"https://origin.rootz.global/static/filing/0001818382-23-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"YWN5dGUuY29t/images/2025-04-04_logo.svg --- EX-99.1 2 huma-20230324xexx991.htm EX-99.1 Exhibit 99.1 Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update -- Enrollment Nearing Completion in Human Acellular Vessel (HAV) Phase 23 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in Hemodialysis Patients  -- Multiple publications and scientifi","filed_date":"2023-03-24","accession":"0001818382-23-000014","full_text":"https://origin.rootz.global/static/filing/0001818382-23-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"which was used to repay in full the Companys existing obligations under the Loan Agreement with SVB. The Company will also be entitled to receive up to approximately $110.0million in subsequent installments subject to the terms and conditions set forth in the Purchase Agreement, as follows: (i) $20.0million upon the Companys biologics license application (BLA) for an indication in vascular trauma be","filed_date":"2023-08-14","accession":"0001818382-23-000114","full_text":"https://origin.rootz.global/static/filing/0001818382-23-000114.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"rd in January 2021 entitling her to purchase 1,312,984 shares of Humacytes common stock, all of which have vested as of the date of this Proxy Statement. This stock option vested in equal annual installments on each of the first three anniversaries of November 9, 2020, and was subject to acceleration upon a corporate transaction (as defined in the 2015 Plan). Humacyte also agreed to reimburse Dr. Nik","filed_date":"2025-04-29","accession":"0001818382-25-000066","full_text":"https://origin.rootz.global/static/filing/0001818382-25-000066.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"which was used to repay in full the Companys existing obligations under the Loan Agreement with SVB. The Company will also be entitled to receive up to approximately $110.0million in subsequent installments subject to the terms and conditions set forth in the Purchase Agreement, as follows: (i) $20.0million upon the Companys biologics license application (BLA) for an indication in vascular trauma be","filed_date":"2023-11-09","accession":"0001818382-23-000162","full_text":"https://origin.rootz.global/static/filing/0001818382-23-000162.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":40,"match_count":5,"context":"herefor by the Company or by any such Holder, or (3) the Trustee shall become incapable of acting or shall be adjudged a bankrupt or insolvent or a receiver of the Trustee or of its property shall be appointed or any public officer shall take charge or control of the Trustee or of its property or affairs for the purpose of rehabilitation, conservation or liquidation, then, in any such case, (A) the Company by a Board Resolution","filed_date":"2025-09-12","accession":"0001104659-25-089607","full_text":"https://origin.rootz.global/static/filing/0001104659-25-089607.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"which was used to repay in full the Companys existing obligations under the Loan Agreement with SVB. The Company will also be entitled to receive up to approximately $110.0million in subsequent installments subject to the terms and conditions set forth in the Purchase Agreement, as follows: (i) $20.0million upon the Companys BLA being accepted on or prior to March 31, 2024, (ii) $40.0million, at the","filed_date":"2023-05-12","accession":"0001818382-23-000030","full_text":"https://origin.rootz.global/static/filing/0001818382-23-000030.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"on leaders (e.g. Denver, Baltimore Shock- Trauma). &#x25AA; DOD Priority Designation &#x25AA; Accelerated Approval Pathway &#x25AA; 47 patients enrolled as of December 31, 2021 2022 Completion of enrollment, top-line results Late-2022 File BLA for Vascular Trauma 2023 BLA approval for Vascular Trauma Expected Milestones1 | | | | 15 HAV in AV Access for Dialysis Phase 3 Trial Underway | | | | 16 TRADI","filed_date":"2022-01-10","accession":"0001104659-22-002717","full_text":"https://origin.rootz.global/static/filing/0001104659-22-002717.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":40,"match_count":5,"context":"at the second annual meeting of stockholders. The term of office of the third class of directors, consisting of Rajiv Shukla, will expire at the third annual meeting of stockholders. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our bylaws as it","filed_date":"2021-05-14","accession":"0001213900-21-026404","full_text":"https://origin.rootz.global/static/filing/0001213900-21-026404.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":40,"match_count":5,"context":"at the second annual meeting of stockholders. The term of office of the third class of directors, consisting of Rajiv Shukla, will expire at the third annual meeting of stockholders. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our bylaws as it","filed_date":"2021-02-16","accession":"0001213900-21-009571","full_text":"https://origin.rootz.global/static/filing/0001213900-21-009571.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HUMA","company":"Humacyte, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":37,"match_count":4,"context":"re immaterial during the periods presented. Legal Matters The Company currently is not aware of any legal proceedings or claims that management believes will have, individually or in the aggregate, a material adverse effect on the Companys business, financial condition, results of operations, or cash flows. Indemnification To the extent permitted under Delaware law, the Company has agreed to indemnify its directors and","filed_date":"2023-05-12","accession":"0001818382-23-000030","full_text":"https://origin.rootz.global/static/filing/0001818382-23-000030.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"33f258539cee4d2681636cf991e905a94020f8a7ef8ea5f041014a3d65fa89f9","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"a403133089806db2d4dee8da514cdd9c7f963baf843eb4b2421978e0fb65e20c","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":492,"hourly_limit":500,"remaining":8,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}